REL:LSERELX PLC Analysis
Data as of 2026-03-10 - not real-time
£2,646.00
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
RELX PLC trades at £26.46 (2646 p) just below its 50‑day SMA (≈£26.50) while holding a healthy RSI of 60 and a bullish MACD histogram, suggesting short‑term upside momentum despite a broader bearish trend. The stock’s trailing P/E of 23.6 sits well under the industry average of 29.5, and it delivers a solid 2.56% dividend yield with a payout ratio around 57%, indicating sustainable income. Analyst consensus is strongly positive – 15 analysts rate it a “strong buy” with median target £36.00, implying ~35% upside. Recent material news adds further catalyst: a £450 m non‑discretionary share buy‑back programme and an announced dividend increase to £0.48 per share, both likely to support price appreciation.
Risk considerations include high 30‑day volatility (~70%), a substantial net‑debt position (debt‑to‑equity >300%), and sector‑specific regulatory exposure, but the company’s low beta (≈0.28) and strong free cash flow generation mitigate market‑wide shocks.
Risk considerations include high 30‑day volatility (~70%), a substantial net‑debt position (debt‑to‑equity >300%), and sector‑specific regulatory exposure, but the company’s low beta (≈0.28) and strong free cash flow generation mitigate market‑wide shocks.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish MACD histogram despite bearish trend
- Upcoming dividend increase and £450 m buy‑back programme
- Price near resistance with upside potential to analyst targets
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong analyst consensus and median price target above current level
- Attractive valuation relative to industry peers (lower P/E)
- Sustainable dividend yield and solid free cash flow
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Consistently high ROE and operating margins
- Diversified global revenue streams reducing geographic concentration
- Ongoing capital return initiatives (dividends and buy‑backs) supporting shareholder value
Key Metrics & Analysis
Financial Health
Revenue Growth1.20%
Profit Margin21.53%
P/E Ratio23.6
ROE70.51%
ROA12.49%
Debt/Equity304.06
P/B Ratio2033.8
Op. Cash Flow£2.8B
Free Cash Flow£2.2B
Industry P/E29.5
Technical Analysis
TrendBearish
RSI60.2
Support£1,991.00
Resistance£2,679.00
MA 20£2,369.85
MA 50£2,650.42
MA 200£3,310.43
MACDBullish
VolumeStable
Fear & Greed Index75.89
Valuation
Fair Value£1,352.06
Target Price£3,733.00
Upside/Downside41.08%
GradeFair
TypeBlend
Dividend Yield2.56%
Risk Assessment
Beta0.28
Volatility69.82%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.